About this podcast:
Recorded at the 2025 DPHARM conference, this state of the union panel convenes site, technology and pharma to discuss: 

• Different models and the pros and cons of the deployment models
• What makes a great patient matching solution
• Predicting what the future growth of this segment looks like
• The role of AI in this space

About this podcast: 
Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies. 

For more information, go to IO360summit.com.

About this podcast: 
Recorded at the 2025 CRAACO meeting, UNC Lineberger’s Comprehensive Cancer Center shares  an initiative to allow local HCPs to still provide clinical care to patients but decentralized research elements to the university system, following the FDA’s change in guidance on Form FDA 1572, which stopped requiring local healthcare professionals (HCPs) involved in DCTs to be listed if they’re only performing standard-of-care. 


Dr J Kaitlin Morrison talks about the process from an initial pilot of two sites to more than 23 today, providing cancer patients across the state the opportunity to access clinical trials. Specifically:

• How they are managing relationships with sites
• How they’re monitoring research elements
• Goals, next steps and thoughts for industry sponsors

About this podcast:
This podcast, recorded at the 2025 Patients as Partners Europe meeting, addresses how Novo Nordisk is consolidating patient insights to ensure greater knowledge-sharing, data integrity and traceability, addressing the unmet needs of patients, aligning product outcomes with patient expectations, and more. 

For more information, go to theconferenceforum.org. 

In this podcast, Kate Woda, Conference Director of the Patients as Partners in Clinical Research conference discusses what attendees can expect at the 13th annual event, including key topic areas, session highlights, presenting companies and more. For more information about the upcoming event, full agenda and speakers, visit patientsaspartnersconference.com.

In this podcast, featuring a panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs with recent M&A and partnership experience share those experiences as well as how CMOs of other small to midsize emerging biotech companies can support the conversations and operations that take place throughout the process of business development. Specifically:

• Different kinds of BD deals to be aware of
• How the CMO fits into various phases of transactions
• Appreciating how different c-suite colleagues and direct reports experience these transactions
• The different pharma teams CMOs will interact with
• What happens after the acquisition

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss conjugation and bioconjugation approaches to make ASOs and small molecules more tolerable while improving targeting. Technologies discussed include ADCs, PDCs, SMDCs, VDCs, RDCs and AOCs. Specifically they address:

• Biological and chemical challenges for these therapies
• Building out scalable manufacturing and a regulatory strategy
• Hurdles to overcome to get products to market

To learn more about the PODD Conference, please visit Drug-Delivery.org.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° about how to strategically approach hiring FTEs, insourcing, outsourcing and contracting to be appropriately prepared for the different stages of a biotech companies development from preclinical to early stage to late stage trials to commercialization. Specifically:

• Balancing the mix of hires and outsourcing
• Hiring for skillsets to enable efficiency without overhiring
• Reactive vs proactive hiring
• Building in a stage appropriate way but also hiring in time for later stages

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

While lipid nanoparticles are the most clinically advanced drug delivery system for nucleic acid therapeutics, they are only one tool in a toolbox of potential delivery vehicles.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss additional tools, including polymeric nanoparticles, protein-based nanoparticles and extracellular vesicles with a focus on:

• Where LNPs potentially fall short
• Where different tools can enable therapeutic delivery
• Challenges to achieving meaningful clinical impact for these different vehicles
• Building out a portfolio of delivery vehicles

To learn more about the PODD Conference, please visit Drug-Delivery.org.

About this podcast: 
This podcast comes from the DPHARM 2025 meeting. Pfizer details how they jointly co-designed and implemented an EDC/CDMS platform that’s fit for purpose, and analysis data set. This session focuses on:

• Engaging all stakeholders in designing the platform
• The evolution of the platform focus: the transition from the majority of data coming from EDC to 3/4 of the data from third party sources
• Impact of the advanced data analysis capabilities for risk management
• Review of impact on initial studies now using the platform 

For more information, go to DPHARMconference.com. 

About this podcast: 
Preliminary survey results conducted by the Tufts CSDD focus on the strategic and structural growth of new trial sites and partnerships in bringing trials directly to the local communities. The preliminary survey findings also shed light on the strategic and structural growth of these new trial sites and partnerships, offering valuable insights into the evolving global clinical trial landscape.

The significant shift towards bringing clinical trials directly to local communities through various innovative models is noteworthy. Many new clinical trial execution models have been introduced during the past decade including site staff embedded within clinical care settings, remote sites, retail pharmacies, urgent care facilities, and mobile units going directly into local communities. 

This session comes from the 2025 Partnerships with Sites Summit. 

About this podcast:
This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center. 

Dr Rosenberg focuses on: 

• The background and previous data of immune checkpoint blockade as monotherapy and in combination with chemotherapy, in urothelial cancer
• The potential role of Immunogenic Cell Death and whether it has a clinical impact on patient care and creating an anti-tumor immune response
• Enfortumab vedotin, an ADC targeting Nectin-4

For more information, go to IO360summit.com.

About this podcast:
This presentation from the 2025 IO360º Summit focuses on the immunological effects of radiopharmaceuticals, presented by Chaitanya Divgi, Sr Strategic Expert, Therapeutic Innovation, at Novartis. 

Specifically, this podcast dives deeper into: 

• An introduction to radioligand therapy
• A focus on PSMA-targeted radionuclide therapy
• Prelimary work on the relationship between systemic radiation therapy and immune effects at the tumor level 

For more information, visit IO360summit.com 

About this episode:
In this podcast, Dr Penny Heaton, Global Head of the Johnson and Johnson Office of the Chief Medical Officer, discusses: 

• J&J’s approach to patient centricity across the enterprise
• Her thoughts on balancing balancing safety and risk/benefit ratios with more engaged patients and more complex science
• Moving risk benefit assessments earlier into clinical development and the necessary change management
• Incorporating multiple streams of data for the purpose of creating medicines that truly address patient needs in the real world

For more information, go to PatientsasPartnersConference.com. 

In this podcast, Nicole Murphy, EVP and Head of Pharmaceutical Operations & Technology at Biogen, discusses:

• Cross-functional collaboration to deliver value
• How Biogen is using AI to enhance innovation
• Supply chain simplification
• Biogen's partnership philosophy as it relates to drug delivery
• Their recent $2 billion manufacturing investment in the Research Triangle Park
• And Biogen's acquisition of Alcyone Therapeutics 

It's an enlightening look into what real leadership in drug delivery, manufacturing and supply chain management looks like. 

For more information, go to Drug-Delivery.org.

In this podcast, Kate Woda, Conference Director of the Immuno-Oncology 360° Summit, discusses what attendees can expect at the 12th annual event, including key topic areas, session highlights, presenting companies and more.

For more information about the upcoming event, full agenda and speakers, visit IO360Summit.com.  

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with CMOs and advisory solutions firms about how CMOs can work with consultants and fractional talent to stay on budget while getting the expertise needed. Specifically:

• Different profiles of fractional consultants
• What to look for in a consultant and how to ensure alignment with the team
• Scoping the role of fractional talent and iterating as company needs evolve
• How to best work with firms representing fractional talent
• Advice for CMOs thinking about consulting

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

About this podcast:
This podcast dives deep into the fundamentals of antibody-drug conjugate design, specifically focusing on the selection of targeting antibodies, cytotoxic drugs, and linkers. Presenter Dr Deepa Pakianathan highlights key strategies for constructing ADCs and the critical differentiating features that enhance therapeutic efficacy and safety. 

For more information, go to IO360summit.com.

About this podcast:
This podcast comes from the 2025 Patients as Partners in Clinical Research conference. 

This panel discussion demonstrates how patient advocates are bridging the divide at the site level to improve patient representation in clinical trials. More specifically, this podcast focuses on: 

• Strategies for overcoming limited resources and lack of infrastructure, which can hinder inclusive clinical trial participation
• Successful models for empowering local leaders and leveraging community-based networks to increase participation
• Evaluating the impact of outreach and engagement efforts on enrollment representation and overall care equity
• And more

For more information, go to PatientsAsPartnersConference.com.

About this podcast: 
Liz Thompson, Global Development Leader, Senior Clinical Development Scientist at Roche, presented how the organization had delivered a single, cohesive protocol amendment categorization process to reduce the number of amendments and create a continuous improvement strategy, all to speed up timelines and reduce costs. This presentation comes from the September 2025 DPHARM: Disruptive Innovations to Modernize Clinical Research program. 

More specifically, Ms Thompson discusses how Roche is: 

• Leveraging historical amendment data to enable study teams to understand why protocols are being amended
• Utilizing a visual data science platform to generate insights from data to make better data-driven decisions
• Applying retrospective learning into current protocols to curb the need for amendments
• Building in business value 

For more information, go to DPHARMconference.com.